文献速递前列腺增生与排尿功能障碍

水刀消融治疗中小体积前列腺患者的良性前列腺梗阻:首个法国水刀消融临床注册研究12个月结果

Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French Aquablation Clinical Registry.
PubMed 文献 · Eur Urol · 2019-07-05

该前瞻性多中心注册研究纳入30例因良性前列腺梗阻接受水刀消融的患者,评估围手术期及12个月功能结局。结果显示水刀消融可行、安全、有效,能在无技术经验的多位术者中提供即刻良好的功能结果,与既往研究结果相似。

要点

  • 水刀消融治疗良性前列腺梗阻在无既往技术经验的多位术者中可行、安全且可重复。
  • 术后6个月IPSS平均改善15.6分(95%CI 13-18.2),改善持续至12个月。
  • 术后新发射精功能障碍发生率为26.7%,未报告尿失禁或新发勃起功能障碍。

核心结论

  • 该临床注册研究证实水刀消融可行、安全、有效,提供即刻良好的功能结果,且尽管术者既往无该技术经验,结果与既往研究相似。

研究设计与样本

  • 前瞻性注册研究,2017年9月至2018年1月期间在三家不同泌尿中心纳入30例因良性前列腺梗阻拟行手术的患者接受水刀消融。
  • 水刀消融使用Aquabeam系统(Procept BioRobotics,美国加州红木城),联合经直肠前列腺影像引导与机器人按定制组织切除及高压盐水射流,术者定义治疗区域后自动执行切除。

主要发现

  • 中位手术时间和切除时间分别为30.5(24-35)分钟和4(3.1-4.9)分钟。
  • 中位导尿时间为43(23-49)小时,中位住院时间为2(2-4)天。
  • IPSS评分在6个月时改善至3(1-6),平均变化15.6分(95%CI 13-18.2),IPSS改善持续至12个月。
  • 最大尿流率在12个月时改善至20.4(17-26)ml/s。
  • 6个月时Clavien-Dindo 2级和3级事件发生率为13.3%,未报告尿失禁或新发勃起功能障碍,术后新发射精功能障碍发生率为26.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aquablation has emerged as a novel ablative therapy combining image guidance and robotics for targeted waterjet adenoma resection. OBJECTIVE: To describe a standardised technique of aquablation in the treatment of benign prostatic obstruction (BPO), and to report the perioperative and 1-yr functional outcomes obtained by multiple surgeons with no previous experience of the technique. DESIGN, SETTING, AND PARTICIPANTS: Between September 2017 and January 2018, patients referred to three different urological centres for BPO surgical management were prospectively enrolled to undergo an aquablation procedure. SURGICAL PROCEDURE: Aquablation was performed using the Aquabeam system (Procept BioRobotics, Redwood Shores, CA, USA) that combines transrectal prostatic image guidance and robotics bespoke tissue resection with a high-pressure saline jet. The surgeon defines the area of treatment, and the resection is executed automatically. MEASUREMENTS: The primary endpoint was the change in total International Prostate Symptom Score (IPSS) score at 6 and 12mo. Functional outcomes were assessed at 1, 3, 6, and 12mo with IPSS, International Index of Erectile Function (IIEF)-15, Sexual Health Inventory for Men, and Male Sexual Health Questionnaire questionnaires and uroflowmetry. RESULTS AND LIMITATIONS: Thirty patients were enrolled in the study. The median operative time and resection time were 30.5 (24-35) and 4 (3.1-4.9)min, respectively. The median catheterisation time was 43 (23-49)h. The median hospitalisation stay was 2 (2-4)d. The IPSS score improved to 3 (1-6) at the 6mo, with a mean change of 15.6 points (95% confidence interval 13-18.2). IPSS improvements persisted at month 12. The maximum urinary flow rate improved to 20.4 (17-26)ml/s at 12mo. The 6-mo rates of Clavien-Dindo grade 2 and 3 events were 13.3%. There were no reports of incontinence or de novo erectile dysfunction. Postoperative de novo ejaculatory dysfunction was observed in 26.7% of patients. CONCLUSIONS: This clinical registry confirmed that aquablation was feasible, safe, and effective, and provided immediate good functional results and similar outcomes to those of prior studies despite the lack of surgeons' previous experience with the technique. PATIENT SUMMARY: Aquablation is feasible, safe, and reproducible with promising outcomes for treating benign prostatic enlargement.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Misrai V, Rijo E, Zorn KC, et al. Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French Aquablation Clinical Registry. Eur Urol. 2019. PMID: 31281024. doi:10.1016/j.eururo.2019.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。